CVD Benefits Reported in 2019 ADA Guidelines
Adapted from Cardiac benefits in Diabetes Therapy: Comparing SGLT2 Inhibitors and GLP-1 Agonists
By Samuel Grossman, BS Pharm, PharmD, CDE, FAADE

GLP-1 RA
- Exenatide ER
- Semaglutide
- Liraglutide

SGLT2
- Canagliflozin
- Empagliflozin